Ellen
Reilly

Reilly is the Chief Executive Officer and a board member of Sware, a Boston company building Res_Q, a platform that automates the GxP validation life sciences companies are legally required to perform. She took the top job in 2023 and, less than a year later, helped close a $6 million Series B that brought the company's total funding to roughly $26 million. In October 2025, Sware shipped an AI-powered version of Res_Q, pushing further into automated, intelligent compliance.

The problem she talks about most is one most people outside the industry have never heard named: validation debt. It is Sware's phrase for the accumulated, unpaid cost of testing, release work, and business requirements that piles up quietly every time a company adopts or updates regulated software. Left unattended, it slows everything - how fast a drug moves through development, how quickly a manufacturer can bring a new system online, how nimble a company can be when technology shifts underneath it.

Reilly's argument is that companies have been told, wrongly, that they must choose between moving fast and staying compliant. Sware's stated mission is to turn GxP validation "from a necessary burden into an operational advantage." In practice that means centralizing validation in one system, adding data-centric reporting and intelligent risk assessment, opening the platform through APIs, and shipping dozens of automation packages so routine testing does not have to be rebuilt by hand each time.

She is not a technologist who wandered into the field. Reilly has spent roughly four decades in life sciences, and she began exactly where Sware now operates - in Quality IT, doing automation implementation and computer system validation. Over the years she held roles at large pharmaceutical companies, including Roche, and worked in a life sciences and technology advisory capacity at PwC. Before Sware, she led the creation and launch of DocuSign's Part 11 product, a module built to help quality and IT leaders meet their FDA and regulatory obligations.

That history is why she calls leading Sware "a full circle moment." The work she did by hand at the start of her career is now the work her company automates for a living. It is an unusual founding-level advantage - she is building from the exact problem she once lived, not from a market she studied from the outside.

Her yardstick for whether any of it is working is refreshingly low-tech. "We know the impact we're making for our clients because we hear from them directly and see the results," she has said. No vanity metrics, no press-release math - the phone call from a customer who shipped faster is the proof. Sware's own case studies put numbers to it: up to 75% acceleration in validation and 40% reductions in time.

Sware sits at 867 Boylston Street in Boston's Back Bay, backed by investors including First Analysis, LRVHealth, New Stack Ventures and Insight Partners. The company has roughly 69 employees and works across the healthcare, life sciences, and medical device sectors. Reilly's leadership team includes co-founder and Chief Quality Officer Bryan Ennis and Chief Commercial Officer Evan Raggi.

What Reilly is really selling is a change in how the industry thinks about a task it has long treated as a cost. She has watched validation move from paper filing cabinets to the cloud over the length of her career. Her bet is that the companies that validate fastest will be the ones that innovate fastest - and that quality and speed, framed correctly, were never really enemies at all.